2-imidazol-1-yl-N,N-dimethylacetamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-imidazol-1-yl-N,N-dimethylacetamide
• 化学式: C₇H₁₁N₃O
• mdl: MFCD01081884
• 分子量: 153.18
• InChiKey: YBBYEOHQBDWFQR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.428
• 拓扑面积：
  38.1
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF
  申请人：Kokubo Masaya

  公开号：US20120207765A1

  公开（公告）日：2012-08-16

  A compound represented by general formula (I): a salt thereof, a solvate thereof, or a prodrug thereof wherein all symbols are as defined in the specification has an antagonistic activity against CXCR4 and is therefore useful as a preventive and/or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, systemic erythematosus, retinopathy, macular degeneration, pulmonary fibrosis, transplanted organ rejection, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiac/vascular disease (for example, arteriosclerosis, myocardial infarction, stenocardia, cerebral infarction, chronic arterial occlusive disease, etc.), metabolic diseases, and cancerous diseases (for example, cancer, cancer metastasis, etc.), a preventive and/or therapeutic agent for cancerous diseases or infections, or an agent for regeneration therapy.

  通式（I）所代表的化合物：其盐、溶剂化物或前药物，其中所有符号均如规范中所定义，具有对CXCR4的拮抗活性，因此可用作预防和/或治疗CXCR4介导的疾病，例如炎症和免疫性疾病（例如类风湿性关节炎、关节炎、系统性红斑狼疮、视网膜病变、黄斑变性、肺纤维化、移植器官排斥等）、过敏性疾病、感染（例如人类免疫缺陷病毒感染、获得性免疫缺陷综合症等）、心理神经疾病、脑部疾病、心脏/血管疾病（例如动脉硬化、心肌梗死、心绞痛、脑梗死、慢性动脉闭塞性疾病等）、代谢性疾病和癌症性疾病（例如癌症、癌症转移等），是用于癌症性疾病或感染的预防和/或治疗剂，或再生疗法的剂。
• COMPOUND HAVING ACIDIC GROUP WHICH MAY BE PROTECTED, AND USE THEREOF
  申请人：Kusumi Kensuke

  公开号：US20090192182A1

  公开（公告）日：2009-07-30

  A compound represented by general formula (I): a salt thereof, a solvate thereof, or a prodrug thereof wherein all symbols are as defined in the specification. The compound of the present invention has antagonistic activity against CXCR4 and is therefore useful as a preventive and/or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, systemic erythematosus, retinopathy, macular degeneration, pulmonary fibrosis, transplanted organ rejection, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiovascular disease, metabolic diseases, cancerous diseases (for example, cancer, cancer metastasis, etc.), or an agent for regeneration therapy.

  化合物的普通公式（I）所代表的化合物：其盐，其溶剂化合物，或其前药。其中所有符号均如规范所定义。本发明的化合物具有对CXCR4的拮抗活性，因此可用作预防和/或治疗CXCR4介导的疾病的药物，例如，炎症和免疫性疾病（例如，类风湿性关节炎，关节炎，系统性红斑狼疮，视网膜病变，黄斑变性，肺纤维化，移植器官排斥等），过敏性疾病，感染（例如，人类免疫缺陷病毒感染，获得性免疫缺陷综合症等），精神神经疾病，脑部疾病，心血管疾病，代谢性疾病，癌症（例如，癌症，癌症转移等），或再生治疗药物。
• Chloropyridylcarbonyl derivatives and their use as microbiocides
  申请人：NIHON BAYER AGROCHEM K.K.

  公开号：EP0763530A1

  公开（公告）日：1997-03-19

  Novel chloropyridylcarbonyl derivatives of the formula in which Hetis nis 1 or 2, R1is hydrogen, optionally substituted C1-6 alkyl, optionally substituted C2-6 alkenyl, optionally substituted C3-6 alkynyl, optionally substituted phenyl or optionally substituted pyrimidinyl, and R2 and R3,independently of each other, are hydrogen or C1-4 alkyl, and acid addition salts and metal salt complexes thereof, processes for the preparation of the new compounds and their use as microbicides.

  式中的新型氯吡啶羰基衍生物 其中 Hetis 为 1 或 2、 R1 是氢、任选取代的 C1-6 烷基、任选取代的 C2-6 烯基、任选取代的 C3-6 烷炔基、任选取代的苯基或任选取代的嘧啶基，以及 R2 和 R3 相互独立地为氢或 C1-4 烷基、 及其酸加成盐和金属盐络合物、 新化合物的制备工艺及其作为杀微生物剂的用途。
• BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1961744B1

  公开（公告）日：2013-04-17
• US5849767A
  申请人：——

  公开号：US5849767A

  公开（公告）日：1998-12-15